Probiotic in Infant Growth, Allergy and Immunity Study - Trial NCT06412042
Access comprehensive clinical trial information for NCT06412042 through Pure Global AI's free database. This phase not specified trial is sponsored by Wecare Probiotics Co., Ltd. and is currently Not yet recruiting. The study focuses on Healthy,Infant ALL. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Wecare Probiotics Co., Ltd.
Timeline & Enrollment
N/A
Jun 15, 2024
Sep 25, 2024
Primary Outcome
Changes in gut microbiota
Summary
To evaluate the intervention effects of Bifidobacterium animalis subsp. lactis strain BLa80
 in promoting growth and development (including gut microbiota and physical growth and
 development) of healthy infants and young children across different age groups, enhancing
 immune function, improving allergy incidence, and analyzing the safety of BLa80 in relation
 to infant growth and development, allergy incidence, and gut microbiota.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06412042
Non-Device Trial